Deep in your brain, neural stem cells that once produced fresh neurons have essentially retired. By your 60s, the factory that builds new brain cells has practically shut down. But a team at the National University of Singapore just found the protein responsible for that shutdown — and when they restored it, those retired stem cells went right back to work.
The study, published February 12th in Science Advances, identifies a protein called DMTF1 (cyclin D-binding myb-like transcription factor 1) as the key molecular switch. Led by Dr. Liang Yajing under Assistant Professor Derrick Sek Tong Ong, the research maps the entire chain reaction behind age-related neural stem cell dormancy.
Here’s how it works: as we age, the telomeres — protective caps on the ends of our chromosomes — get shorter with each cell division. Eventually they get so short that cells stop dividing. The Singapore team discovered that this telomere shortening specifically depletes DMTF1 levels. Without DMTF1, two helper genes called Arid2 and Ss18 go quiet. These genes are part of the SWI/SNF chromatin remodeling complex, which normally loosens tightly packed DNA to expose growth-related genes. When they’re inactive, growth genes stay silenced and stem cells remain dormant.
The breakthrough: when researchers artificially restored DMTF1 in aged stem cells, the cells started dividing again — even though the telomeres remained short. DMTF1 essentially overrides the retirement notice, bypassing the consequences of telomere aging without reversing the aging itself.
This is still early-stage research done in cell cultures and mouse models. The next steps involve testing whether boosting DMTF1 can improve learning and memory in living animals without increasing brain tumor risk. Professor Ong described the work as “in its infancy.”
But the implications are profound. If a single protein can reawaken dormant neural stem cells, future therapies might target DMTF1 to combat Alzheimer’s, age-related cognitive decline, and other neurodegenerative conditions. The brain’s repair machinery isn’t broken — it’s just been switched off. And now we may know which switch to flip.
The Molecular Clock of Brain Aging
Your brain contains roughly 86 billion neurons, but it also harbors a small but critical population of neural stem cells — the cells that can divide and produce new neurons, a process called neurogenesis. In youth, these stem cells are active, continually replenishing the brain’s supply of fresh neurons, particularly in the hippocampus (the memory center) and the subventricular zone (which produces neurons for the olfactory system).
By middle age, the vast majority of these stem cells have entered a state called quiescence — they’re alive but dormant, no longer dividing. By your 60s and 70s, neurogenesis has slowed to a trickle. This decline correlates strongly with age-related cognitive impairment: slower learning, weaker memory formation, and reduced mental flexibility. The question that has obsessed neuroscientists for decades is whether this decline is irreversible or simply a molecular switch that could be flipped back.
The DMTF1 Discovery
The team at the National University of Singapore, led by Dr. Liang Yajing under Assistant Professor Derrick Sek Tong Ong, identified DMTF1 (cyclin D-binding myb-like transcription factor 1) as a master regulator of neural stem cell activity. DMTF1 levels decline sharply with age in both mouse and human brain tissue. When the researchers restored DMTF1 levels in aged mice — either through genetic manipulation or protein delivery — dormant neural stem cells reactivated and began producing new neurons.
The mechanism is elegant. DMTF1 normally suppresses the expression of cell cycle inhibitors — molecular brakes that prevent stem cells from dividing. As DMTF1 declines with age, these brakes accumulate, locking stem cells into quiescence. Restoring DMTF1 releases the brakes, allowing the cell division machinery to restart.
Klotho: The Anti-Aging Protein
DMTF1 isn’t the only protein linked to brain aging reversal. Klotho, discovered in 1997 and named after the Greek Fate who spins the thread of life, has emerged as one of the most promising targets in aging research. People who naturally carry a variant of the klotho gene that produces more of the protein score higher on cognitive tests at every age and appear to be protected against Alzheimer’s disease, even when they carry genetic risk factors like APOE4.
In 2023, a team at UCSF led by Dr. Dena Dubal demonstrated that a single injection of a klotho protein fragment improved cognitive function in both young and old mice for approximately two weeks. The mice performed better on spatial learning tasks, novel object recognition, and contextual fear conditioning — standard tests of hippocampal function.
The mechanism appears to involve enhanced synaptic plasticity — the ability of neural connections to strengthen in response to experience, which is the cellular basis of learning. Klotho enhances NMDA receptor function, increases the expression of GluN2B (a receptor subunit associated with cognitive flexibility), and promotes the growth of new dendritic spines — the tiny protrusions where neurons receive signals from other neurons.
From Mice to Humans: The Translation Challenge
Both DMTF1 and klotho results are currently limited to animal models. Translating mouse neuroscience to human therapies has a notoriously poor track record — approximately 95% of neurological drugs that work in mice fail in human clinical trials. Mouse brains are smaller, simpler, and age on different timescales. A mouse cognitive improvement that lasts two weeks might not scale to meaningful human benefit.
However, several factors make researchers cautiously optimistic. First, both proteins are conserved across species — humans have DMTF1 and klotho, and their levels decline with age just as they do in mice. Second, the klotho genetic variant that enhances cognition in humans provides independent confirmation that the pathway matters in people. Third, the mechanisms involved (NMDA receptor function, synaptic plasticity, neurogenesis) are well-established in human neuroscience.
The Broader Landscape of Brain Rejuvenation
DMTF1 and klotho are part of a growing portfolio of brain aging interventions. Young blood plasma transfusions (parabiosis) have shown cognitive benefits in aged mice, and human trials are underway. Exercise increases BDNF (brain-derived neurotrophic factor), which promotes neurogenesis and synaptic plasticity. Senolytics — drugs that clear senescent (zombie) cells from the brain — have shown cognitive improvement in mouse models.
The convergence of multiple approaches targeting different aspects of brain aging suggests that age-related cognitive decline isn’t a monolithic process with a single cause, but rather a constellation of molecular changes that can be individually addressed. The dream is a combination therapy that restores neural stem cell activity (DMTF1), enhances synaptic plasticity (klotho), clears cellular debris (senolytics), and supports new neural growth (BDNF via exercise).
Why This Matters
The global cost of dementia care exceeds $1.3 trillion annually and is projected to double by 2030. Roughly 55 million people worldwide live with dementia, and that number is expected to reach 139 million by 2050 as populations age. If proteins like DMTF1 and klotho can meaningfully delay or reverse age-related cognitive decline, the impact would be measured not just in dollars but in tens of millions of people retaining their independence, memories, and identities for longer.
We’re still in early days — human clinical trials for klotho-based therapies are in planning stages, and DMTF1 is even earlier in the pipeline. But the fundamental discovery is profound: the brain’s aging clock can be influenced. The stem cells haven’t died — they’re sleeping. And we’re learning how to wake them up.
Frequently Asked Questions
What is klotho protein?
Klotho is a protein that decreases with age and is associated with cognitive function. Named after the Greek Fate who spins the thread of life, people with naturally higher klotho levels show better cognitive performance at every age. Mouse studies show that boosting klotho can reverse age-related cognitive decline.
Can klotho protein reverse brain aging?
In animal studies, a single injection of klotho protein fragment improved cognitive function in both young and old mice for about two weeks. The protein appears to enhance synaptic plasticity and NMDA receptor function. Human clinical trials are being planned, but translating mouse results to humans is uncertain.
Related Episodes
If you enjoyed this episode, check out these related deep dives: